Entellus Medical (NASDAQ:ENTL) will post its quarterly earnings results after the market closes on Monday, February 19th. Analysts expect Entellus Medical to post earnings of ($0.44) per share for the quarter.
Shares of Entellus Medical (NASDAQ:ENTL) opened at $24.06 on Friday. The firm has a market cap of $620.05, a price-to-earnings ratio of -18.65 and a beta of -0.02. Entellus Medical has a 12 month low of $11.47 and a 12 month high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.
In other Entellus Medical news, Director Brian E. Farley sold 101,319 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $23.85, for a total transaction of $2,416,458.15. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Thomas P. Williamson sold 2,449 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $24.08, for a total transaction of $58,971.92. The disclosure for this sale can be found here. Insiders sold a total of 108,942 shares of company stock worth $2,599,658 in the last ninety days. 7.70% of the stock is currently owned by insiders.
ENTL has been the topic of several recent analyst reports. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Zacks Investment Research downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. Finally, BidaskClub downgraded shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.25.
COPYRIGHT VIOLATION WARNING: This report was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/18/entellus-medical-entl-scheduled-to-post-earnings-on-monday.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.